Transgene Announces Option for TG4010 not exercised

29-04-2014 Business Wire HealthComments (0)


Transgene SA (Paris:TNG) (NYSE-Euronext: TNG) today announced that Novartis has informed the Company that it will not exercise its option for the global development and commercialization rights to TG4010 MUC1 targeted cancer immunotherapy. As a result, Transgene retains all rights to the program. “We regret that Novartis has chosen not to use its exclusivity period to opt-in and become our global partner for TG4010,” said Philippe Archinard,

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top